We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




China to Expand Neonatal Screening

By Labmedica staff writers
Posted on 07 Aug 2006
PerkinElmer Wallac Inc. More...
(Turku, Finland) has signed a five-year agreement with the Ministry of Health of the People's Republic of China (Bejing), to help expand neonatal screening for genetic diseases in seven of China's least economically developed provinces.

The program, which begins this year, is part of the Chinese Ministry of Health's Sino-Finnish neonatal screening cooperation program.

Under the terms of the five-year agreement, the Chinese Ministry of Health will purchase assay kits that will be used on the Victor multilabel plate readers donated by PerkinElmer for genetic testing. As a result, labs will have a powerful system for the detection and direct quantification of DNA and proteins. This is the second neonatal screening program between the Chinese Ministry of Health and PerkinElmer, a provider of neonatal screening technology. In the first program, initiated in 1996, PerkinElmer donated five neonatal screening systems and ran a neonatal educational program in China.

From now until the end of 2006, the implementation plans will be mapped out. During the years 2007-2009, training courses and information seminars will take place, and in the year 2010 a final assessment of the cooperation will be made.

Sources from the Ministry of Health said that neonatal disease screening began in the early 1980s in China. After implementation of laws and regulations to improve the health quality of newborn babies, hospitals started to screen babies for hypothyroidism (CH) and phenylketonuria (PKU). However, neonatal screening is still unsatisfactory in some urban and less-developed areas.

In 2005, PerkinElmer systems were used to screen more than 50% of the four million babies who received newborn screenings in China. This expanded initiative will enable China's Ministry of Health to increase the screening rate by at least 30% annually in each of the seven provinces involved: Hubei, Heilongjiang, Liaoning, Guangxi, Shanxi, Qinghai, and Guizhou. In addition to screening, the enhanced program will provide health education to physicians and lab staff at local screening centers, thereby improving the knowledge of genetic diseases and developing technical skills.

"As part of our ongoing commitment to newborn screening and maternal health worldwide, we are pleased to be supporting China's Ministry of Health once again with this neonatal screening effort,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. "We are particularly excited that this partnership will reach families in seven of China's most underserved provinces, helping to reduce neonatal morbidity and mortality.”



Related Links:
PerkinElmer Wallac

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.